Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
1 other identifier
observational
150
1 country
1
Brief Summary
The summary of this study is to know which HPV types are present in genital warts in Argentinean population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2012
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2012
CompletedFirst Posted
Study publicly available on registry
May 15, 2012
CompletedStudy Start
First participant enrolled
June 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedResults Posted
Study results publicly available
December 21, 2015
CompletedDecember 21, 2015
December 1, 2015
2.2 years
May 11, 2012
December 9, 2014
December 18, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Human Papillomavirus (HPV) Types in External Genital Warts (EGW)
150 biopsies with histological diagnosis of genital warts were analyzed by PCR to detect HPV type
4 months
Eligibility Criteria
Women with genital warts
You may qualify if:
- women between 15 and 45 years old, with External Genital Warts
You may not qualify if:
- women taking corticoid therapy, having an immunosuppressed disease, pregnancy, cancer related to HPV, VIN confirmed by histology, other sexually transmitted infection, HIV+ known
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Buenos Aireslead
- Merck Sharp & Dohme LLCcollaborator
Study Sites (1)
IFER
Buenos Aires, Buenos Aires, 1425, Argentina
Biospecimen
Biopsy specimens will be held in a formol 10% solution and will be sent to the pathologist. A portion of each sample will be processed for histological analysis, which will be performed by one pathologist. The remainder of each specimen will be saved to extract DNA for PCR analysis
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Laura Fleider
- Organization
- University of Buenos Aires
Study Officials
- PRINCIPAL INVESTIGATOR
Laura A Fleider, MD
University of Buenos Aires
- PRINCIPAL INVESTIGATOR
Laura A Fleider, MD
Institute of Gynecology and Fertility
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Physician
Study Record Dates
First Submitted
May 11, 2012
First Posted
May 15, 2012
Study Start
June 1, 2012
Primary Completion
August 1, 2014
Study Completion
August 1, 2014
Last Updated
December 21, 2015
Results First Posted
December 21, 2015
Record last verified: 2015-12